YOLT-204
Phase 1Small molecule
YOLT-204 is one of 26 small molecule programs targeting Hemoglobinopathies. It is currently in Phase 1.
2
Indications
2
Total Trials
2
Active Trials
25
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
22 competitors in Beta-Thalassemia
#DrugCompanyPhaseTrials
1Exjade
NovartisApproved
Thalomid
Bristol-Myers SquibbApproved
Droxia
TTheravia
Approved
Desferal
Jazz PharmaceuticalsApproved
Glucophage
EMD SeronoApproved
Viagra
VViatris Specialty LLC
Approved
Vidaza
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Approved
Ferriprox
Chiesi Farmaceutici S.p.A.Approved
CTX001
Vertex PharmaceuticalsPhase 3
ACE-536
Bristol-Myers SquibbPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Beta-Thalassemia1 trial
A Pilot Study on the Safety and Efficacy of YOLT-204 for Transfusion-Dependent Beta-Thalassemia
Not yet recruiting·FFirst Affiliated Hospital of Guangxi Medical University·Phase 1·NCT06678165·3 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for YOLT-204. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details